The Pre-POINT study is the first study that offers an immunization-like
treatment to delay or even prevent autoimmunity and type 1 diabetes.
The preventative treatment with insulin is intended to stop the
development of diabetes autoantibodies
in children with high genetic risk. The aim of the study is to find the
most appropriate dose of the insulin to do
this.
The child will take the insulin by mouth as a powder on a daily basis. Insulin given in these ways does NOT lower blood glucose, but it is supposed to influence the immune system, similar to an immunization.
Pre-POINT is an international study. Professor Dr. Ezio Bonifacio at the Center for Regenerative Therapies Dresden (CRTD), Germany, is the coordinator. There are study centres in Germany, Austria, Great Britain, the USA and Canada.
The child will take the insulin by mouth as a powder on a daily basis. Insulin given in these ways does NOT lower blood glucose, but it is supposed to influence the immune system, similar to an immunization.
Pre-POINT is an international study. Professor Dr. Ezio Bonifacio at the Center for Regenerative Therapies Dresden (CRTD), Germany, is the coordinator. There are study centres in Germany, Austria, Great Britain, the USA and Canada.
Child taking part will be asked to take the treatment for between 3 and
18 months.
After completion of the Pre-POINT study we expect to start the POINT study. In the POINT study we will investigate the protective effect of an insulin vaccination over a longer period of time and whether we are able to prevent the onset of the diabetes. Children who participate in Pre-POINT will also be able to take part in POINT.
After completion of the Pre-POINT study we expect to start the POINT study. In the POINT study we will investigate the protective effect of an insulin vaccination over a longer period of time and whether we are able to prevent the onset of the diabetes. Children who participate in Pre-POINT will also be able to take part in POINT.
All
children who are aged between 18 months and 7 years and have a high
genetic risk of developing diabetes, which means they have
| • | at least one brother or sister or both mother and father have type 1 diabetes |
| • | not developed diabetes autoantibodies or diabetes |
There are study centres
in Germany, Austria, the UK, the USA and
Canada.